Immuno-Oncology Compound Library 
Traditional cancer therapies include surgery, radiation therapy, and chemotherapy. With the rapid development of science and technology in medicine, new cancer therapies such as immunotherapy, targeted therapy, radiofrequency ablation for cancer are actively developed to help patients fight cancer. Cancer immunotherapy, also known as immuno-oncology, is a form of cancer treatment that uses the power of the body's own immune system to prevent, control, and eliminate cancer. Science magazine—America's leading scientific journal—has deemed cancer immunotherapy the 2013 "Breakthrough of the Year," beating out nine other contenders.
There are several types of immunotherapy, including: Non-specific immunotherapies, CAR T-cell therapy, cancer vaccines, checkpoint inhibitors, etc. Most cancer immunotherapy agents being developed or approved are engineered T cells targeting tumors or mostly antibody-based biologics that target the immune checkpoint cascade. The success of these biologics in the clinic is now inspiring the discovery and development of small molecules that act on intracellular targets affecting immuno-modulatory pathways in cancer. Small molecule agents as opposed to biologics that steer or enable the immune system to attack cancer cells, represent an emerging area of R&D focus in the oncology drug development industry. Small molecules are being investigated as stand-alone agents and synergistically with approved biologics because of the ability of small molecules to reach intracellular targets and the greater patient convenience offered by their oral bioavailability. The foundation for the pursuit of small molecule immune therapies for cancer is the wide spectrum of cells and their molecular pathways that are used by the immune system to suppress or enhance cellular immunity. Such novel immunotherapeutic approaches can either negate immune suppression in the tumor milieu or facilitate cytolytic lymphocyte responses to the tumor.
AnyMol's Immuno-Oncology Compound Library carefully collects 523 bioactive compounds targeting intracellular pathways modulating the innate and adaptive immune response is a powerful tool for your research and drug discovery.
- All products & services are for research use only. Not for human or veterinary or therapeutic use.
- Pack Size
- 1 mg
- 10 μL x 10 mM (in DMSO)
- 30 μL x 10 mM (in DMSO)
- 50 μL x 10 mM (in DMSO)
- 100 μL x 10 mM (in DMSO)
Technical Information
Library Compound Information
Excel 
SDF - Product Description:
- A unique collection of 523 compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening；
- Targets include PD-1/PD-L1, HER2, STAT3, CTLA4, IDO, STING, CCR, CXCR, TLR, etc.
- Detailed compound information with structure, target, and biological activity description；
- NMR and HPLC validated to ensure high purity and quality.
- Packaging And Storage:
- Powder or pre-dissolved DMSO solutions in 96/384 well plate with optional 2D barcode
- Shipped with blue ice
- This compound library is provided at a concentration of 10 mM in DMSO. A small number of compounds may be provided in different solvents or concentrations due to solubility or stability requirements. Please refer to the specific product information for details.
